Scientists use CRISPR to supercharge immune cells against tough cancers
NCT ID NCT04426669
Summary
This early-phase trial tested a new cell therapy for people with advanced gastrointestinal cancers that had stopped responding to standard treatments. Researchers collected a patient's own immune cells from a tumor, used CRISPR gene editing to remove a molecular 'brake' (CISH), and then infused these boosted cells back into the patient. The main goals were to see if this approach was safe and if it could shrink tumors.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Masonic Cancer Center, University of Minnesota
Minneapolis, Minnesota, 55455, United States
Conditions
Explore the condition pages connected to this study.